

Curriculum Vitae

Personal information **Clemens Mittmann**

Work experience

1. Employer: University Hospital Hamburg_Eppendorf
 - Start date: 011996
 - End date: 062003
 - Position: Research Assistant
 - Activities: Basic research in cardiovascular pharmacology, clinical pharmacology, experimental pharmacology and toxicology, lectures for medical students
 - Country: Germany
2. Employer: Federal Institute for Drugs and Medical Devices
 - Start date: 072003
 - End date:
 - Position: Vice Head/Head of Area/Clinical Assessor
 - Activities: Regulatory activities mainly in the area of cardiovascular medicinal products and antidiabetics, assessment, scientific advice, membership in regulatory working groups at the EMA, currently member of the cardiovascular working party (CVSWP) and alternate member of the SAWP
 - Country: Germany
3. Employer: University Hospital Hamburg_Eppendorf
 - Start date: 011995
 - End date: 121995
 - Position: Scholarship holder of the German Heart Foundation e.V.
 - Activities: Basic research in cardiovascular pharmacology and clinical cardiology, clinical pharmacology, experimental pharmacology and toxicology, lectures for medical students
 - Country: Germany
4. Employer: University Hospital Hamburg_Eppendorf
 - Start date: 101992
 - End date: 121994
 - Position: Internship
 - Activities: Clinical Cardiology
 - Country: Germany

Education and training

1. Subject: University Hospital Hamburg_Eppendorf
 - Start date: 2002
 - End date: 2002
 - Qualification: Board Certification as Medical Specialist for Clinical Pharmacology, and as a Medical Specialist for Pharmacology und Toxikology
 - Organisation:
 - Country: Germany
2. Subject: Eberhard Karls University, Tübingen and Ludwig_Maximilians_University in Munich, Medical state examination (Grade 2)
 - Start date: 1985
 - End date: 1992
 - Qualification: Studies of Medicine
 - Organisation:
 - Country: Germany
3. Subject: University of Columbia, Missouri, U.S.A.
 - Start date: 1990
 - End date:
 - Qualification: Studies of Medicine
 - Organisation: Medical Student in Clinical Cardiology (2 months)
 - Country: United States
4. Subject: Harvard Medical School, Boston and University of Chicago, U.S.A.
 - Start date: 1992
 - End date: 1992
 - Qualification: Studies of Medicine
 - Organisation: Medical Student (2 _ 3 months respectively)
 - Country: United States
5. Subject: University of Hamburg
 - Start date: 011995
 - End date: 121997
 - Qualification: Postgraduate studies in molecular biology
 - Organisation: Molecular Biology, examination 1998 (grade: 1)
 - Country: Germany

Additional information

Publications

I. Doctoral thesis Charakterisierung der Bindungseigenschaften des partiellen β -Adrenozeptor Agonisten Xamoterol und seiner Wirkung auf die Adenylatcyclaseaktivität und Kontraktionskraft an menschlichem Myokard.

II. Original publications

1. Böhm M, **Mittmann C**, Schwinger RHG, Erdmann E (1989) Xamoterol and the failing heart. *Lancet* ii: 1213_1214
2. Böhm M, **Mittmann C**, Schwinger RHG, Erdmann E (1990). Effects of xamoterol on inotropic and lusitropic properties of the human myocardium and on adenylate cyclase activity. *Am Heart J* 120: 1381_1392
3. **Mittmann C**, Böhm M, Schwinger RHG, Erdmann E (1991) Die Therapie der Herzinsuffizienz mit β -Adrenozeptor Antagonisten und partiellen Agonisten. Experimentelle Daten zur Wirkung von Xamoterol am menschlichen Herzen. *Der Kassenarzt* 31: 32_36
4. Schwinger RHG, Böhm M, **Mittmann C**, Erdmann E (1991) Evidence for a sustained effectiveness of sodium_channel activators in failing human myocardium. *J Mol Cell Cardiol* 23: 461_471
5. Eschenhagen T, Friedrichsen M, Gsell S, Hollmann A, **Mittmann C**, Schmitz W, Scholz H, Weil J, Weinstein LS (1996) Regulation of the human *Gia_2* gene promotor activity in embryonic chicken cardiomyocytes. *Basic Res Cardiol* 91 (Suppl 2): 41_46
6. Weil J, Eschenhagen T, Magnussen O, **Mittmann C**, Orthey E, Scholz H, Schäfer H, Scholtysik G (1997) Reduction of myocardial myoglobin in bovine dilated cardiomyopathy. *J Mol Cell Cardiol* 29: 734 _ 751
7. **Mittmann C**, Münstermann U, Weil J, Böhm M, Herzig S, Nienaber C, Eschenhagen T (1998) Analysis of gene expression patterns in small amounts of human ventricular myocardium by a multiplex RNase protection assay. *J Mol Med* 76: 133 _140
8. Weil J, Eschenhagen T, Hirt S, Magnussen O, **Mittmann C**, Remmers U, Scholz H (1998) The Frank-Starling mechanism is preserved in terminally failing human hearts and does not correlate with ANP expression. *Cardiovasc Res* 37: 541 _ 548
9. Handrock R, Schröder F, Hirt S, Haverich A, **Mittmann C**, Herzig S (1998) Single_channel properties of L_type calcium channels from failing human ventricle. *Cardiovasc Res* 37: 445_455
10. Weil J, Eschenhagen T, Fleige G, **Mittmann C**, Orthey E, Scholz H (1998) Localization of preproenkephalin mRNA in rat heart: selective gene expression in left ventricular myocardium. *Am J Physiol* 275:H378_H384
11. Grimm M, Gsell S, **Mittmann C**, Nose M, Scholz H, Weil J, Eschenhagen T (1998) Inactivation of *Gia* proteins increases arrhythmogenic effects of α -adrenergic stimulation in the heart. *J Mol Cell Cardiol* 30: 1917_1928
12. Kähler J, Ewert A, Weckmüller J, **Mittmann C**, Köster R, Orzechowski HD, Paul M, Meinertz T, Münzel T (2000) Oxidative stress increases synthesis of big endothelin_1 by activation of the endothelin_1 promoter. *J Mol Cell Cardiol* 32:1429_1437
13. **Mittmann C**, Schüler C, Chung_C_H, Höppner G, Nose M, Kehrl J_H, Wieland T (2001) Evidence for a short form of RGS3 preferentially expressed in the human heart. *Naunyn Schmiedebergs Arch Pharmacol*. 2001; 363: 456_463
14. Kähler J, Ewert A, Weckmüller J, Stobbe S, **Mittmann C**, Köster R, Paul M, Meinertz T, Münzel T (2001) Oxidative stress increases endothelin_1 synthesis in human coronary artery smooth muscle cells. *J Cardiovasc Pharmacol*; 38: 49_57
15. Patten M, Bünemann J, Thoma B, Krämer L, Thoenes M, Stübe S, **Mittmann C**, Wieland T (2002) Endotoxin induces desensitization of cardiac Endothelin_1 receptor signaling by increased expression of RGS4 and RGS16. *Cardiovasc Res* 53: 156 _ 164
16. **Mittmann C**, Chung CH, Höppner G, Michalek C, Nose M, Schüler C, Schuh A, Eschenhagen T, Weil J, Pieske B, Hirt S, Wieland T (2002) Expression of 10 RGS proteins in human myocardium: Functional characterization of an upregulation of RGS4 in heart failure. *Cardiovasc Res* 55: 778 _ 786
17. Kähler J, Sill B, Köster R, **Mittmann C**, Orzechowski HD, Münzel T, Meinertz T (2002) Endothelin_1 mRNA and protein in vascular wall cells is increased by reactive oxygen species. *Clin Sci* 103 (Suppl 1): 176S_178S
18. **Mittmann C**, Pinkepank G, Stamatelopoulou S, Wieland T, Nürnberg B, Hirt S, Eschenhagen T (2003). Differential Coupling of m_Cholinoceptors to Gi/Go Proteins in Human Myocardium *J Mol Cell Cardiol* 35:1241 _ 1249
19. Liu X, Benda N, **Mittmann C**, and Koch A (2024) Combining Recurrent and Terminal Events Into a Composite Endpoint May Be Problematic. *Statistics in Biopharmaceutical Research* 1–8

III. Reviews, editorials and position papers in peer reviewed journals

1. **Mittmann C**, Eschenhagen T, Scholz H. (1998) Cellular and molecular aspects of contractile dysfunction in heart failure. *Cardiovasc Res* 39: 267_275
2. Wieland T, **Mittmann C**. (2003) Regulators of G protein signalling: multifunctional proteins with impact on signalling in the cardiovascular system *Pharmacology and Therapeutics* 97: 95 – 115
3. **Mittmann C**. (2004) Molecular basis of AV block and cardiac malformations (Editorial) *Cardiovascular Research* 64: 1_2
4. Elliott P, Cowie M.R., Franke J., Ziegler A., Antoniadis C., Bax J., Bucciarelli_Ducci C., Flachskampf F. A., Hamm C., Jensen M. T., Katus H., Maisel A., McDonagh T., **Mittmann C**, Muntendam P., Nagel E., Rosano G, Twerenbold R., and Zannad F. (2021) Development, validation, and implementation of biomarker testing in cardiovascular medicine state_of_the_art: proceedings of the European Society of Cardiology—Cardiovascular Round Table *Cardiovascular Research* 117: 1248–1256
5. Jankowska EA1 Andersson T, Kaiser-Albers C, Bozkurt B, Chioncel C, J.S. Coats AJS, Hill L, Koehler F, Lund LH, McDonagh T, Metra M, **Mittmann C**, Mullens W, Siebert U, Solomon SD, Volterrani M and McMurray JJV. (2023) Optimizing outcomes in heart failure: 2022 and beyond *ESC Heart Failure* 10: 2159–2169
6. Dorbala S, Adigun R, Alexander KM, Brambatti M, Cuddy SAM, Dispenzieri AQ, Dunnmon P, , Emdin M, Ezzeddine OFA, Falk RH, Fontana M, Grodin JL, Guthrie S, Jerosch-Herold M, Hofling AA, Hsu K, Lin G, Masri A, Maurer MS, **Mittmann C**, Prasad K, Quarta CC, Race J_M, Rajendran JG, Ruberg FL, Sachdev V, Sanchorawala V, Signorovitch J, Sirac C, Soman P, Sorensen, Sperry BW, Stephens AW, Stockbridge NL, Vest J, Wall JS, Wechalekar A, Welsh C, Lousada I. (2025) Development of Imaging Endpoints for Clinical Trials in AL and ATTR Amyloidosis: Proceedings of the Amyloidosis Forum. *JACC Cardiovasc Imaging*. Online ahead of print
7. Szymanski P, Lüscher TF, Weidinger F, Bhalla N, Goncalves A, Himmelman A, Kraus BJ, Boersma E, D'Atri F, Gunther P, Irs A, Kirchhof P, **Mittmann C**, Mihaylova B, Mol P, Prescott E, Simon T, Tijssen J, Van Heetvelde M, Vrijlandt P, Zannad F. (2025) Addressing Unmet Medical Needs in Cardiology: Perspectives from a European Society of Cardiology Cardiovascular Round Table. submitted

IV. Other articles in medical and scientific journals

1. Mittmann C. (1998) Allergische Rhinitis durch Betablocker Ärztliche Praxis 50: 9
2. Mittmann C. (1999) Buchbesprechung: Arzneiverordnung in der Schwangerschaft und Stillzeit von H. Spielmann, H. Steinhoff, Ch. Schaefer, R. Bunjes Hamburger Ärzteblatt 4/99: 190
3. Mittmann C. (2000) Buchbesprechung: Angiotensin_II_Rezeptorantagonisten: Pharmakologie und Therapeutische Anwendung H. Grobecker Wissenschaftliche Verlagsgesellschaft, Stuttgart 1999 Hamburger Ärzteblatt
4. Mittmann C. (2001) Welche Antihypertonika wirken 24 Stunden lang? Ärztliche Praxis 52: 10
5. Mittmann C. (2002) Husten durch ACE_Hemmer? Ein Fall für Sartane Ärztliche Praxis 53: 13
6. Mittmann C. (2002) Sartane plus NSAR – Achtung, Hyperkaliämie Ärztliche Praxis 53: 14
7. Mittmann C. (2002) Bitterer Geschmack hat viele Ursachen Ärztliche Praxis 78: 10
8. Mittmann C. (2002) Nitratsalben bei Analfissuren Ärztliche Praxis 85: 12
9. Mittmann C. (2003) Statine senken basale CRP_Werte moderat Ärztliche Praxis 91: 12
10. Mittmann C. (2003) Kolloidales Silber Ärztliche Praxis 92: 14
11. Mittmann C. (2003) Rationaler Einsatz von Herzglykosiden Ärztliche Praxis 94: 10
12. Mittmann C. (2005) Tailored testing for future standard Regulatory issues in pharmacogenetics and pharmacogenomics World Pharmaceutical Frontiers Vol. 2, 59 _ 63
13. Roth A. I., Mittmann C. (2006) Diazepam nie im letzten Trimenon Ärztliche Praxis Gynäkologie 3: 21
14. Mittmann C. (2016) Riociguat, eine genaue Diagnostik ist entscheidend. Bulletin für Arzneimittelsicherheit Bulletin zur Arzneimittelsicherheit 2016; 3: 3 – 9 Presentations with published abstract: 61 Presentations without abstract: 34

Projects

Memberships

Research award of the Deutsche Herzstiftung e.V. 1997. Professional affiliations : Member of _ European Society of Cardiology _ Deutsche Gesellschaft für Kardiologie, Herz- und Kreislau fforschung (DGK) _ German Society of Experimental and Clinical Pharmacology and Toxicology (DGPT)

Other Relevant Information